Disease modifying agents for multiple sclerosis.
OBJECTIVE
To summarize major clinical trials which evaluate the efficacy and safety data of approved disease modifying agents for the treatment of various types of multiple sclerosis.


METHODS
A MEDLINE (1966 to August 2008) search of clinical trials using the terms multiple sclerosis, interferon, glatiramer, mitoxantrone and natalizumab was performed. A manual bibliographic search was also conducted. English-language articles identified from the searches were evaluated. New agents under investigation in phase 3 clinical trials were identified using www.clinicaltrials.gov. STUDY SELECTION #ENTITYSTARTX00026;


METHODS
Relevant information was identified and selected based on clinical relevance and evidence-based strength. Prescribing information leaflets were used to provide usual dosage, contraindications, precautions, monitoring parameters and other relevant drug-specific information.


RESULTS
Interferon beta products are more efficacious for the treatment of relapsing-remitting multiple sclerosis. Interferon beta 1-b also delayed the time to diagnosis of definite multiple sclerosis and reduced brain lesion burden in patients with clinical isolated syndrome. Glatiramer and natalizumab have both established efficacy in relapsing forms of multiple sclerosis; whereas mitoxantrone is more commonly used in patients with advanced disease. There are limited data the comparative efficacy among different disease modifying agents. New agents currently under investigation have showed promising results and may offer more treatment options in the future.


CONCLUSIONS
MS is a complex and devastating disease with challenging treatment considerations and approaches. Interferon beta products continue to be the mainstay of therapy in many patients, however, other treatments are proving to be at least as effective in the management of various types of MS. Newer compounds are being developed and studied with much anticipation and promise for the clinical management of the disease.
St. John's University College of Pharmacy and Allied Health Professions, Queens, NY, USA.
Olga
O
Hilas
Priti N
PN
Patel
Sum
S
Lam
Ann Neurol. 1994;36 Suppl:S12-4
8017871
Neurology. 1996 Apr;46(4):907-11
8780061
N Engl J Med. 2006 Mar 2;354(9):899-910
16510744
Neurology. 2001 Aug 28;57(4):731-3
11524494
Neurology. 2007 Jun 12;68(24 Suppl 4):S8-11
17562848
Acta Neurol Scand. 2007 Aug;116(2):96-9
17661794
J Neurol. 2006 Sep;253(9):1160-4
16990994
Neurology. 1998 Mar;50(3):701-8
9521260
Neurology. 1993 Apr;43(4):655-61
8469318
N Engl J Med. 2006 Mar 2;354(9):911-23
16510745
Neurology. 2004 Feb 24;62(4):628-31
14981183
Neurology. 2006 Apr 11;66(7):1056-60
16510769
Ann Neurol. 2005 Dec;58(6):840-6
16283615
Acta Neurol Scand. 2006 May;113(5):283-7
16629762
Neurology. 2006 Oct 10;67(7):1242-9
16914693
Neurology. 2007 Jun 12;68(24 Suppl 4):S16-22
17562846
Mult Scler. 2006 Jun;12(3):309-20
16764344
Neurology. 2002 Aug 27;59(4):636-9
12196668
Neurology. 2004 Nov 23;63(10):1788-95
15557491
Neurology. 1998 Sep;51(3):765-72
9748024
N Engl J Med. 1987 Aug 13;317(7):408-14
3302705
Lancet. 1998 Nov 7;352(9139):1491-7
9820296
Neurorehabil Neural Repair. 2002 Dec;16(4):307-20
12462762
N Engl J Med. 2003 Jan 2;348(1):15-23
12510038
Ann Pharmacother. 2007 Oct;41(10):1660-8
17785617
Neurology. 2001 Jun 26;56(12):1628-36
11425926
Mult Scler. 2004 Oct;10(5):507-10
15471365
Mult Scler. 2006 Feb;12(1):72-6
16459722
J Neuroimmunol. 2003 Mar;136(1-2):1-8
12620637
Brain. 1989 Feb;112 ( Pt 1):133-46
2917275
Mult Scler. 2001 Dec;7(6):349-53
11795454
Ann Neurol. 2001 Jul;50(1):121-7
11456302
Pharmacol Ther. 2006 Jan;109(1-2):198-209
16095713
Ann Neurol. 1992 Mar;31(3):333-6
1637140
BMJ. 2000 Aug 19-26;321(7259):490-4
10948033
J Neurol. 1997 Mar;244(3):153-9
9050955
Neurology. 2000 Sep 12;55(5):689-93
10980735
Neurology. 1992 May;42(5):991-4
1579256
Neurology. 2002 Nov 26;59(10):1496-506
12451188
J Neurol Sci. 2002 May 15;197(1-2):51-5
11997066
Neurology. 1995 Jul;45(7):1268-76
7617181
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12877-82
14569025
Neurologist. 2007 Jul;13(4):182-7
17622909
Ann Neurol. 2001 Mar;49(3):290-7
11261502
J Neuroimmunol. 1999 Sep 1;99(1):131-41
10496186
J Neurovirol. 2000 May;6 Suppl 2:S85-7
10871792
Acta Neurol Scand. 2005 Oct;112(4):234-7
16146492
Lancet. 2002 Dec 21-28;360(9350):2018-25
12504397
Ann Pharmacother. 2006 Oct;40(10):1814-21
16985095
Neurology. 1995 Jul;45(7):1277-85
7617182
Eur J Neurol. 2005 Jun;12(6):425-31
15885045
Am J Med Genet. 1988 Mar;29(3):533-41
3376997
Arch Neurol. 2005 May;62(5):785-92
15883267
Ann Neurol. 1996 Mar;39(3):285-94
8602746
N Engl J Med. 2006 Sep 14;355(11):1124-40
16971719
Neurology. 1993 Apr;43(4):662-7
8469319
Am J Epidemiol. 1978 Nov;108(5):386-93
727208
Arch Neurol. 1999 Sep;56(9):1138-42
10488816
Ann Neurol. 1994;36 Suppl:S54-60
8017889
N Engl J Med. 2000 Sep 28;343(13):938-52
11006371
Acta Neurol Scand. 2006 Jun;113(6):378-86
16674604
Lancet. 2002 Apr 27;359(9316):1453-60
11988242
Neurology. 2006 Jan 24;66(2):275-7
16434675
Ann Neurol. 1994 Dec;36 Suppl 2:S211-7
7998790
Mult Scler. 2001 Feb;7(1):33-41
11321192
Lancet. 1998 Nov 7;352(9139):1498-504
9820297
Neurology. 2004 Nov 23;63(10):1779-87
15557490
Biochimie. 2007 Jun-Jul;89(6-7):899-902
17574320
Lancet Neurol. 2004 Dec;3(12):709-18
15556803
Clin Neuropharmacol. 2002 Jan-Feb;25(1):11-5
11852290
Ann Neurol. 1998 Apr;43(4):499-506
9546332
Ann Neurol. 2007 Jan;61(1):14-24
17262850
Neurology. 2007 Jun 12;68(24 Suppl 4):S3-7
17562847
N Engl J Med. 2000 Sep 28;343(13):898-904
11006365
Mult Scler. 2006 Dec;12(6):731-7
17263000
Neurol Clin. 1995 Feb;13(1):119-46
7739500